Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Effects of interleukin-6 blockade on the development of autoimmune thyroiditis in nonobese diabetic mice.

Authors: Mori, K  Yoshida, K  Mihara, M  Ohsugi, Y  Nakagawa, Y  Hoshikawa, S  Ozaki, H  Ito, S 
Citation: Mori K, etal., Autoimmunity. 2009 Mar;42(3):228-34.
Pubmed: (View Article at PubMed) PMID:19301205
DOI: Full-text: DOI:10.1080/08916930802709141

We explored the role of interleukin-6 (IL-6) in the development of autoimmune thyroiditis in nonobese diabetic (NOD) mice, an animal model of Hashimoto's thyroiditis, using anti-mouse IL-6 receptor antibody (MR16-1). Thyroiditis was induced by iodide ingestion or mouse thyroglobulin (Tg) immunization. Mice were injected intraperitoneally with saline, control rat IgG, or MR16-1 (2 or 8 mg). Iodide ingestion did not increase serum IL-6 levels and MR16-1 (2 mg) failed to prevent the development of thyroiditis. In contrast, Tg immunization induced a rapid and significant increase in serum IL-6 levels. While MR16-1 (2 mg) had no effect on Tg-induced thyroiditis, the severity, but not incidence, of thyroiditis was reduced in 8 mg MR16-1-treated mice compared with saline-injected mice. However, thyroiditis development in the 8 mg MR16-1-treated mice was indistinguishable from that in the control IgG-treated mice. MR16-1 (8 mg) did not affect serum anti-Tg antibody levels. These results suggest that IL-6 may play only a minor role in the development of autoimmune thyroiditis in NOD mice.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 2307256
Created: 2009-05-26
Species: All species
Last Modified: 2009-05-26
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.